3388-79-2Relevant articles and documents
TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
-
Paragraph 0275-0277, (2022/02/06)
The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.
COMBINATION THERAPIES FOR TREATMENT OF CANCER
-
Page/Page column 276; 277, (2016/04/09)
Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
INHIBITORS OF KRAS G12C
-
Page/Page column 225, (2015/04/28)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
-
Page/Page column 11, (2008/06/13)
Acetylcholine receptor ligands of formula I wherein D, E and G are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the sam
SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS
-
, (2008/06/13)
The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed
N,N-diacylpiperazine tachykinin antagonists
-
, (2008/06/13)
Diacylpiperazines of general structure STR1 are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
1,4-Diazabicyclo[3.2.1]octanes
-
, (2008/06/13)
The compounds 4-carbethoxy-1,4-diazabicyclo[3.2.1]octane and 4-diethylcarbamyl-1,4-diazabicyclo[3.2.1]octane, said compounds having utility as antifilarial agents.